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Abstract
Background: HIV-1 Gag virus like particles (VLPs) used as candidate vaccines are regarded as inert particles as they
contain no replicative nucleic acid, although they do encapsidate cellular RNAs. During HIV-1 Gag VLP production
in baculovirus-based expression systems, VLPs incorporate the baculovirus Gp64 envelope glycoprotein, which
facilitates their entry into mammalian cells. This suggests that HIV-1 Gag VLPs produced using this system facilitate
uptake and subsequent expression of encapsidated RNA in mammalian cells - an unfavourable characteristic for a
vaccine.
Methods: HIV-1 Gag VLPs encapsidating reporter chloramphenicol acetyl transferase (CAT) RNA, were made in
insect cells using the baculovirus expression system. The presence of Gp64 on the VLPs was verified by western
blotting and RT-PCR used to detect and quantitate encapsidated CAT RNA. VLP samples were heated to inactivate
CAT RNA. Unheated and heated VLPs incubated with selected mammalian cell lines and cell lysates tested for the
presence of CAT protein by ELISA. Mice were inoculated with heated and unheated VLPs using a DNA prime VLP
boost regimen.
Results: HIV-1 Gag VLPs produced had significantly high levels of Gp64 (~1650 Gp64 molecules/VLP) on their
surfaces. The amount of encapsidated CAT RNA/μg Gag VLPs ranged between 0.1 to 7 ng. CAT protein was
detected in 3 of the 4 mammalian cell lines incubated with VLPs. Incubation with heated VLPs resulted in BHK-21
and HeLa cell lysates showing reduced CAT protein levels compared with unheated VLPs and HEK-293 cells. Mice
inoculated with a DNA prime VLP boost regimen developed Gag CD8 and CD4 T cell responses to GagCAT VLPs
which also boosted a primary DNA response. Heating VLPs did not abrogate these immune responses but
enhanced the Gag CD4 T cell responses by two-fold.
Conclusions: Baculovirus-produced HIV-1 Gag VLPs encapsidating CAT RNA were taken up by selected mammalian
cell lines. The presence of CAT protein indicates that encapsidated RNA was expressed in the mammalian cells.
Heat-treatment of the VLPs altered the ability of protein to be expressed in some cell lines tested but did not
affect the ability of the VLPs to stimulate an immune response when inoculated into mice.
Background
Inert virus-like particles (VLPs) made from virus struc-
tural protein(s) are an ideal substitute for live, attenu-
ated and peptide-based virus vaccines, as they present
epitopes in an immunologically relevant context and
lack any replicative nucleic acid. Several VLP-based vac-
cines have been developed against human viruses, such
as the recently-released human papillomavirus (HPV)
vaccines, and the well-established hepatitis B virus
(HBV) vaccines [1-3]. Gag polyproteins of human and
simian immunodeficiency viruses (HIV and SIV) pro-
duced in various expression systems (bacterial, yeast,
insect, mammalian and plant cells) also assemble into
VLPs that bud through plasma membranes to produce
enveloped particles, which strongly resemble immature
virions. These VLPs have been shown to be potent sti-
mulators of both cellular and humoral immune
responses in animal models and therefore are potentially
excellent vaccine candidates [4-11].
During virion assembly, HIV Gag encapsidates two
copies of the viral genomic RNA displaying a HIV
packaging signal called the ψ-site [12-17]. The
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prerequisite for virion assembly and release [18-23]. In
the absence of ψ-site-containing viral RNA, assembling
viral particles still encapsidate high levels of host cell
derived RNA [13,21,21,22,24]. This non-specific RNA
encapsidation is mediated by RNA binding to basic resi-
dues distributed throughout various domains of Gag
[18,19,23,25-28]. Gag proteins with specific mutations in
these domains were shown to be unable to package
RNA, and consequently unable to assemble into parti-
cles [18,23]. RNA has thus been shown to play a key
structural role in virus particle assembly by serving as a
scaffold upon which multiple Gag molecules can assem-
ble [19,23,29-33]. As a result, HIV Gag VLPs produced
in the aforementioned expression systems may thus con-
tain significant levels of encapsidated host cellular RNA.
The primary mode of HIV entry into cells was
assumed to be by Gp120/Gp41-and CD4+ host cell CD4
+ CCR5/CXCR4 receptor-mediated plasma membrane
fusion [34,35]. More recent studies have documented
viral entry into cells mainly via a Gp120/Gp41-indepen-
dent endocytic pathway, with HIV particles shown to be
present within acidified endocytic vesicles destined for
degradation [36-41]. At least 50-90% of viral material
has been shown to enter cells by this Gp120/Gp41-inde-
pendent endosomal pathway when viral particles contain
functional Gp120/Gp41 [36-38,41], which suggests that
the endocytic/degradative pathway is a major entry
route. HIV virions may also be internalised by macropi-
nocytosis in a receptor and pH-independent process
[39,41]; however, only Gp120/Gp41-displaying virions
were shown to access the cytosol, presumably by enga-
ging specific receptors on the internal surface of the
macropinosome/endosome. The general consensus of
HIV cellular entry studies is that, irrespective of the
path of entry into the target cell, successful HIV infec-
tion is dependent on receptor/co-receptor interactions
at the cell surface or within vesicles.
HIV-1 Gag VLPs are often produced in baculovirus-
based insect cell expression systems, which provide an
ideal eukaryotic environment for the production of bio-
logically active recombinant proteins as they enable
post-translational modifications such as proper protein
folding, disulphide bond formation, oligomerisation and
proteolytic cleavage [42]. VLPs that bud from insect
cells accordingly become enveloped with the insect host
cell membrane, which contains abundant baculovirus
Gp64 envelope glycoprotein. These VLPs are said to be
pseudotyped with Gp64. Gp64 is one of the most abun-
dant proteins comprising the baculovirus virion, and is
crucial for infectivity and functionality of the baculovirus
expression system [43]. Gp64 mediates baculovirus entry
into cells via an influenza-like, clathrin-mediated, low
pH-dependent endocytic pathway, where viral and
endosomal membrane fusion occurs subsequent to
endosomal acidification [44-53].
Gp64-mediated baculovirus uptake is not limited to
insect cells. Several studies have demonstrated the abil-
ity of recombinant baculoviruses to enter host mamma-
lian cells, and subsequent gene expression to occur
within these cells. Their uptake has been demonstrated
in vivo in mouse nasal epithelia, mouse skeletal muscle
cells, rabbit endothelial cells, and in vitro in various
mammalian cell lines including HeLa, Vero, BHK-21,
293 T-cells, rat hepatocytes and human hemocytes and
hepatocytes [54-61]. Lentiviral (HIV/MLV) vectors pseu-
dotyped with Gp64 have been shown to be taken up by
mammalian cell lines with the same target cell range as
that observed for recombinant baculoviruses, which
i n c l u d ec e l l so fh e p a t i co r i g i n ,2 9 3T - c e l l s ,H e L aa n d
HuH-7 human cell lines, while haematopoietic cells
were not [62-64]. In addition, Schauber et al [63] and
Sinn et al [64] have demonstrated the efficient gene
transfer potential of Gp64 pseudotyped lentiviral (HIV/
FIV) vectors in vivo.
While endosomal degradation of non-pseudotyped
(Gp160) VLPs subsequent to cellular entry should effec-
tively prevent the transmission and expression of VLP-
contained RNAs, the presence of baculovirus Gp64 on
the surface of Gag VLPs could enable expression of
these RNAs within eventual mammalian vaccine recipi-
ents. The potential delivery and expression of insect
cell-derived nucleic acids by VLPs within a vaccinated
individual is regarded as a problematic trait by vaccine
regulatory bodies such as the United States Food and
Drug Administration (FDA). The FDA specifically
requires vaccine developers to show that VLPs do not
encapsidate “specific” nucleic acid sequences from the
expression system, and especially those encoding VLPs
components.
In this study we tested the ability of insect cell-pro-
duced HIV Gag VLPs to function as a vector for RNA
uptake in several mammalian cell lines. Also, as the
amount of Gp64 on the surface of insect cell-produced
HIV-1 Gag VLPs has not been determined, this study
initially estimated the relative levels of Gp64 per VLP.
This study is the first, to our knowledge, to analyse the
potential transfer and successful expression of encapsi-
dated reporter CAT RNAs from non-replicating Gag
VLPs in mammalian cell lines: previous studies have all
been conducted on more complex live lentivirus models
that carried reporter genes as part of the replicative viral
genome [62,63]. VLPs were heated in an attempt to
inactivate any RNA encapsidated by the VLPs and the
CAT expression in mammalian cells after uptake was
investigated. In addition, we compared the ability of
heat-treated VLPs and unheated VLPs to stimulate an
immune response in mice. GagCAT VLPs were
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to enhance the immunogenicity of these VLPs especially
when used as a booster vaccine after a prime with a
matching DNA vaccine.
Methods
Baculovirus-produced GagCATVLPs
AP r 5 5gag gene encoding the Gag sequence with a
myristoylation signal, derived from the Du422 clinical
isolate [65,66] was human codon-optimised (hmGag;
Operon Technologies (USA)) and cloned into the pFast-
Bac™ Dual (pFBD) baculovirus insect cell expression
vector (Invitrogen) under the p10 promoter to produce
the pFBDGag construct. The pFBDGagCAT construct
was generated by cloning a chloramphenicol acetyltrans-
f e r a s e( C A T )r e p o r t e rg e n e ,d e r i v e df r o mt h e
pcDNA3.1/Zeo/CAT cloning vector (Invitrogen), into
the gag-containing pFastBac™ Dual construct under the
polyhedrin (PH) promoter (Figure 1a). Baculovirus pro-
duced pFBDGagCAT and control pFBDGag bacmids
were generated in a Spodoptera frugiperda-derived Sf21
cell line (Invitrogen) [7,42,67-70]. Briefly, the Sf21 cells
were maintained as a monolayer at 27°C in TC-100
insect medium (Sigma) supplemented with 10% (v/v)
foetal bovine serum (FBS), 50 μg/ml neomycin, 69.2 μg/
ml penicillin G and 100 μg/ml streptomycin. Sf21 cells
(1 × 10
6 cells/ml) were infected with the recombinant
pFBDGagCAT and control pFBDGag baculovirus at a
multiplicity of infection (MOI) of 2-10, and VLPs were
harvested from 100 ml of culture supernatant 72 h post
infection by means of cross-flow filtration using a cross-
flow filter unit (MidGee™, GE Healthcare) with a 300
kDa cut-off filter cartridge according to the manufac-
turer’s protocol. VLPs were pelleted by centrifugation at
83, 000 × g and resuspended in 300 μlo f1×s t e r i l e
Dulbecco’s phosphate buffered saline (PBS, Sigma
®) and
incubated with 7.5 u RNase A and 1.33 u RNase T1 for
2 h at 37°C [23] to remove any RNA in the surrounding
medium. VLPs were re-purified by centrifugation
through a 20% sucrose cushion at 83, 000 × g and resus-
pended in PBS containing 15% trehalose to maintain
VLP stability.
Electron microscopy of GagCAT VLPs
GagCAT VLPs were visualized using a LEO 912 trans-
mission electron microscope after adsorption onto 200
mesh carbon-coated copper grids stained with 2% uranyl
acetate.
Quantification of Gag and Gp64 of GagCAT VLPs
The purity of VLPs were assessed and Gag concentra-
tion of the GagCAT VLP preparation was measured by
electrophoresis of purified VLPs through a 10% denatur-
ing SDS polyacrylamide gel and western blotting [68].
To quantitate the Gag concentration a serial dilution of
an HIV-1 p17/24 C clade protein standard (ARP695.2,
FIT Biotech, Programme EVA, centre for AIDS reagents,
NIBSC) was included on the gel. Membranes were
probed with a 1/5000 dilution of anti-p24 polyclonal
rabbit antiserum (ARP432, NISBC Centralised Facility
for AIDS reagents, MRC, UK) and a 1/5000 dilution of
an anti-rabbit alkaline phosphatase-conjugated second-
ary antibody (Sigma-Aldrich). Gag protein was visualised
using 5-bromo-4-chloro-3-indolyl phosphate/nitro blue
tetrazolium (BCIP/NBT) (Roche). The Gag concentra-
tion of the GagCAT VLP preparation was estimated by
densitometry which compared the collective density of
all Gag bands with the density of the Gag bands for the
standard using gel imaging software (Gene Genius Bio,
Syngene). The VLPs were resuspended at 1 μgG a g / μl
PBS containing 15% trehalose and stored at -70°C. The
Gp64 content of the GagCAT VLP preparation was
visualized by probing the membrane with a 1/5000 dilu-
tion of a purified mouse anti-baculovirus Gp64 envelope
glycoprotein antibody (Clone: AcV5; eBioscience) and
anti-mouse alkaline phosphatase-conjugated secondary
antibody (Sigma-Aldrich) and developed with BCIP/
NBT. Gp64 was quantitated from Coomassie-stained
gels using serial dilutions of a BSA standard and densi-
tometry as described for quantification of Gag protein
above and variance was determined using Prism 5
(GraphPad).
Inactivation of VLP RNA
For use in cell-uptake experiments, GagCAT VLP sam-
ples were heated at 62°C for 20 minutes (called hVLPs)
based on the method used for heat-inactivating live HIV
particles [71].
Detection and quantitation of CAT RNA
RT-PCR (Access RT-PCR System, Promega) of GagCAT
VLPs and these VLPs after heat treatment (hVLPs) con-
tained 5 μl of the VLP preparation (equivalent to 5 μg
Gag protein) in 100 μla n d1m MM g C l 2 with 50 pmol
of the primers designed to yield a 350 bp product. The
forward and reverse primer sequences used were 5’
GCAATGAAAGACGGTGAGC 3’ and 5’ ATGAACCT-
GAATCGCCAGC 3’, respectively. In vitro-transcribed
CAT RNA was used as a positive control (Ribomax™
Large Scale RNA Production System - T7 kit (Promega).
The cycle profile was as follows: 45°C, 45 min; 94°C, 2
min; 25 cycles of 94°C, 30 sec; 57°C, 30 sec; 72°C, 1 min.
RNA was extracted from GagCAT VLPs after heat
treatment using the RTP Virus DNA-RNA Isolation Kit
(Invitek). Each RNA extraction was carried out using 5
μlo ft h eV L Pp r e p a r a t i o n( e q u i v a l e n tt o5μgG a gp r o -
tein) and the RNA was eluted in 50 μl of extraction kit
elution buffer after which 10 μl was used for real-time
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Figure 1 VLP isolation and quantification. a) Schematic diagram of pFBDGagCAT showing the Gag and CAT open reading frames under the
control of the p10 and pH promoters, respectively. (b) Transmission electron micrograph of purified GagCAT VLPs. Arrows indicate typical
doughnut-shaped VLPs (120 - 150 nm in diameter). Scale bar = 1000 nm. (c) Transmission electron micrographs of Gag VLPs after heating at 62°
C for 20 minutes. Scale bar = 200 nm. (d) Coomassie-stained 10% SDS polyacrylamide gel used to densitometrically quantify Gp64 on in Gag
VLP preparations. Lane 2 contains the Gp64 positive control (*), while lanes 3-6 contain dilutions of BSA at 100, 200, 500 and 1000 ng,
respectively. Lane 7 contains Gag VLPs containing 1000 ng of Gag, showing gp64 (*) and Gag
Pr55 (**). (e) and (f) Comparative western blots of
purified VLP extracts probed with anti-Gag primary antibody (e) and anti-Gp64 primary antibody (f): Lane 2 - HIV-1 p17/p24 C clade protein
standard (ARP695.2); Lane 3 - Gp64 positive control; Lane 4 - Purified GagCAT VLPs. Black arrows indicate the position of the 55 kDa HIV Gag (e)
and 64 kDa VSV Gp64 (f) proteins, respectively. (g) 1% agarose gel showing DNA fragments generated by RT-PCR (lanes 2-4) and PCR (lanes 6-8)
of GagCAT VLPs using CAT-specific primers. Lane 1 - molecular weight marker; Lanes 2 and 6 - 350bp positive control fragments generated
using in vitro-transcribed CAT RNA and CAT DNA for RT-PCR and PCR, respectively; Lanes 3 and 7 - result of negative control experiments
generated by RT-PCR and PCR of Gag VLP RNA extracts, respectively; Lanes 4 and 8 - results of RT-PCR and PCR using GagCAT VLP RNA extracts,
respectively.
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Mix One-Step real-time RT-PCR kit (Quantace) and a
Rotor-Gene RG-3000A real-time PCR machine (Corbett
Research). Reactions (25 μl) contained in vitro-tran-
scribed CAT RNA as a standard or 10 μlo ft h eR N A
extracted from the GagCAT VLP preparation, 50 mM
MgCl2 and 50 pmol of forward and reverse primers to
amplify a 150 bp DNA fragment. The forward and
reverse primer sequences used were 5’
AGATGTGGCGTGTTACGGT 3’ and 5’ ATGAACCT-
GAATCGCCAGC 3’, respectively. The reaction profile
u s e dw a sa sf o l l o w s :4 9 ° C ,4 5m i n ;9 5 ° C ,1 0m i n ;3 0
cycles of 95°C, 15 sec, 57°C, 15 sec and 72°C, 15 sec. All
real-time RT-PCR data was analysed using the Rotor-
gene 6, Version 6.0 (Build 27) software (Corbett
Research).
GagCAT VLP uptake by mammalian cell lines
Murine macrophages (RAW 264.7), baby hamster kidney
cells (BHK-21), human embryonic kidney cells (HEK
293) and HeLa cells were maintained as continuous cul-
tures at 37°C in 5% CO2. RAW 264.7 cells were cultured
in RPMI (RPMI 1640+GlutaMAX™-1, Gibco
®)a n d
BHK-21 cells, HEK 293 and HeLa cells were cultured in
DMEM (DMEM+GlutaMAX™-1, Gibco
®). These media
were supplemented with 10% (v/v) foetal calf serum
(Gibco), 1% penicillin G/streptomycin and 1% Fungin
(supplemented culture medium). Twenty four hours
prior to GagCAT VLP uptake the RAW 264.7, BHK-21
and HeLa cell cultures were seeded in 6-well plates
(Nunc™) in 2 ml supplemented culture medium at a
concentration of 0.5 × 10
5 cells/ml per well, while HEK
293 cells were seeded in 6-well plates at 0.2 × 10
5 cells/
ml supplemented culture medium per well. Cells were
washed twice with 2 ml PBS prior to the addition of
G a g C A TV L P si nav o l u m eo f1m lu n s u p p l e m e n t e d
culture medium and incubated at 37°C for 2 h, which
was then replaced with 2 ml of supplemented culture
medium and incubated for 24 h at 37°C after which cell
lysates were prepared and CAT protein content analysed
by ELISA (Roche CAT ELISA kit). Each cell-type trans-
fection was carried out with the same VLP and heated
VLP preparations and the entire experiment was carried
out in triplicate. ELISA plates were analysed using a
PowerWave™ XS ELISA plate reader (BioTek
®)a n d
results analysed using the KCL™ (version 3.4) program
(BioTek
®). Mean values of triplicate assays for a cell
lysate did not vary by more than 5%. Data is presented
as mean responses for 6 replicate uptake experiments.
Immune responses in mice
Female BALB/c mice (8-10w e e k so l d )w e r eu s e dt o
compare immune responses of GagCAT VLPs and
heated GagCAT VLPs (hGagCAT VLPs) when given
alone. The ability of these VLPs to boost a primary
response induced by a matched HIV-1 subtype C DNA
vaccine, pTHGagC [7] was also determined. All mouse
procedures were approved by the UCT Animal Ethics
Committee, (AEC no. 006-007). Plasmid (100 μgD N A )
and VLPs (400 ng Gag protein) in PBS were given as
intramuscular injections in a final volume of 100 μl with
50 μl injected into each hind leg muscle. Spleens were
collected from groups of mice on day 40 after a prime
inoculation on day 0 with pTHGagC and a boost with
either GagCAT VLPs, hGagCAT VLPs or pTHGagC on
day 28. Groups of mice were also left unvaccinated and
then on day 28 vaccinated with GagCAT VLPs or hGag-
CAT VLPs and spleens collected on day 40 to determine
responses to these VLPs only [68]. Splenocyte suspen-
sions were prepared from spleens pooled from 5 mice
per group and red blood cells (RBC) were lysed (RBC
lysing solution, Sigma). IFN-g and IL-2 ELISPOT assays
(BD Pharmingen) were performed according to manu-
facturer’s instructions to assess the frequency of Gag-
specific IFN-g and IL-2 secreting CD8 and CD4 T cells.
Triplicate wells contained 500 000 splenocytes/well in a
final volume of 200 μl R10 medium (RPMI 1640+Gluta-
MAX™-1 with 20 mM HEPES, 10% heat inactivated
FCS, 15 mM b-mercaptoethanol, 1% penicillin G/strep-
tomycin) only to determine background responses or in
this medium with the peptides (> 95% pure; Bachem,
Switzerland) AMQMLKDTI (Gag CD8) or NPPIPV-
GRIYKRWIILGLNK (Gag CD4(13) peptide) or
FRDYVDRFFKTLRAEQATQE (Gag CD4(17) peptide)
[72,73]. Spots were detected using Nova Red substrate
(Vector Labs) then scanned and counted using a CTL
Analyzer (Cellular Technology, OH, USA) with Immu-
nospot Version 3.2 software. The mean number of spots
from triplicate wells ± SD (standard deviation) was cal-
culated and mean background spots were subtracted
then adjusted to spot forming units (sfu) per 10
6 spleno-
cytes ± SD.
Results and discussion
Characteristics of baculovirus-produced GagCAT VLPs
Transfection of Sf21 insect cells with pFBDGagCAT
yielded VLPs that could be harvested by cross-flow fil-
tration from insect cell culture supernatant. Transmis-
sion electron microscopy of the purified VLPs showed
numerous doughnut-shaped particles with diameters
ranging in size from 120 to 150 nm (Figure 1b). A few
baculovirus particles were occasionally observed in sam-
ples of the VLP preparations viewed under the electron
microscope, but not in all fields of view. Although the
ratio of baculovirus particles to VLPs was not calculated,
it was considered too small to interfere with the esti-
mated calculation of Gp64 protein per μgo fG a gp r o -
tein by much. A Coomassie-stained gel of GagCAT VLP
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Gag protein (Figure 1d - lane 7**). The higher band is
thought to be the 64 kDa gp64 protein and the lower
band is a p41 HIV-1 Gag breakdown product which has
been observed in previous work in this laboratory [67].
Western blotting of GagCAT VLPs using an anti-Gag
antibody confirmed the presence of the 55 kDa HIV-1
Gag protein (Figure 1e - lane 4). A western blot of Gag-
CAT VLPs using an anti-Gp64 antibody showed a band
of 64 kDa in size (Figure 1f - lane 4) which confirmed
the association of this protein with the purified GagCAT
VLP preparations. As there was no quantified Gp64
standard available for western blot or ELISA quantita-
tion, the relative amount of Gp64 incorporated into the
GagCAT VLPs per microgram of VLPs Gag protein was
determined densitometrically using quantitated amounts
of BSA on a Coomassie-stained gel (Figure 1d - lanes 3
to 6). The average Gp64 concentration was calculated to
be 383 ± 86 ng Gp64/ug of Gag after analysis of four
separate VLP purifications analysed in triplicate.
CAT RNA in GagCAT VLPs
To determine whether CAT RNA was encapsidated in
the purified GagCAT VLPs, RT-PCR using CAT-specific
primers was carried out on purified GagCAT VLP RNA.
The presence of CAT RNA was shown by successful
amplification of a 350 bp DNA fragment (Figure 1g -
lane 4), corresponding to the positive control, which
was generated using in vitro-transcribed CAT RNA (Fig-
ure 1g - lane 2).
No product was amplified from RNA extracted from
G a gV L P s( F i g u r e1 e-l a n e3a n d7 )w h i c hw e r ep r o -
duced after transfection of Sf21 insect cells with a con-
struct lacking CAT (pFBDGag). To exclude the
possibility that DNA fragments could have resulted from
amplification of contaminating CAT DNA co-purified
from the insect-cell preparation, GagCAT VLPs were
subjected to PCR using CAT-specific primers, which
failed to amplify any product (Figure 1g - lane 8). A 350
bp DNA fragment was observed from amplification of
CAT DNA (lane 6) and no fragment was observed from
amplification of Gag VLP RNA (lane 7), as expected.
The amount of CAT RNA encapsidated by 1 μg of Gag
VLPs was quantitated by real-time RT-PCR using in
vitro-transcribed RNA as a standard. CAT RNA quantita-
tion of nine individual GagCAT VLP preparations
showed that the amount of encapsidated CAT RNA/μg
Gag VLPs varied between individual VLP preparations
(0.1 - 7 ng CAT RNA/μg Gag VLPs) (data not shown).
Expression of encapsidated CAT RNA in mammalian cell
lines
To test whether CAT RNA could indeed be transcribed
and translated into protein in mammalian cells, we
determined the presence ofC A Tp r o t e i ni nB H K - 2 1
cells after transfection with in vitro-transcribed CAT
RNA. CAT RNA transcription and translation was con-
firmed by the detection of CAT in cell lysates (data not
shown). To investigate whether CAT RNA can be
expressed in mammalian cells after uptake of GagCAT
VLPs, VLPs containing 10 ng of CAT RNA were added
to 4 different mammalian cell types and CAT protein
expression levels in cell lysates quantified by CAT
ELISA after 24 hours. The cell lines were selected on
the basis of availability in the laboratory, as well as the
fact that at least 3 of them are known to facilitate entry
of Gp64-pseudotyped viral particles by means of a Gp64
receptor that is present on their outer cell wall
[56,58,74]. Cell lysates prepared from BHK-21, HEK 293
and HeLa cells contained CAT protein (Figure 2). In
contrast, lysates of the murine macrophage cell line
(RAW 264.7), a hematopoietic cell line, known to be
non-receptive to baculovirus Gp64 mediated transfec-
tion [57] did not contain CAT protein after incubation
with the GagCAT VLPs (data not shown). CAT protein
expression levels between the 3 different cell lines ran-
ged from 0.7 - 0.86 ng/ml of CAT, when transfected
with VLPs containing a total 10 ng of CAT RNA respec-
tively (Figure 2).
Effect of heat treatment on expression of encapsidated
CAT RNA in mammalian cell lines
The cellular uptake and subsequent transcription of
GagCAT RNA encapsidated by the VLPs has implica-
tions for their use as a vaccine. It is important to limit
transmission and expression of RNA encapsidated by
VLPs to ensure no production of a protein that may
cause ill effects when VLPs are administered as a vac-
cine. We tested whether heating the VLPs (using a
Figure 2 Expression of encapsidated CAT RNA in mammalian
cell lines. CAT expression levels are shown in BHK-21 (I), HeLa (II)
and HEK 293 (III) cell lysates 24 hours after unheated or heat treated
VLP uptake. Gag VLPs containing 10 ng of CAT RNA were used for
the cell uptake assays in each cell line. Heat treated VLPs were
incubated for 20 min at 62°C. Error bars display the variance
between 3 separate experiments. P values are displayed above each
set of uptake assays.
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particles [71,75]) would impact on the GagCAT tran-
scription and translation after VLP uptake in certain
mammalian cells. Gag VLPs carrying 10 ng of CAT
RNA were incubated at 62°C for 20 minutes prior to
incubation with BHK-21, HEK 293 and HeLa cells.
Twenty four hours following cell uptake, cell lysates
were analysed for CAT expression by CAT ELISA (Fig-
u r e2 ) .L y s a t e so fB H K - 2 1a n dH e L ac e l l sa f t e ru p t a k e
of heat treated VLPs contained significantly reduced (p
< 0.0001) CAT protein levels compared to lysates from
cells that had been incubated with unheated VLPs. On
the contrary, expression of CAT in HEK-293 cells after
uptake of heat treated VLPs was marginally different
from that after uptake by unheated VLPs (Figure 2).
Heat-treated VLPs were not physically or structurally
damaged (Figure 1c). TEM proved them to be intact
doughnut-shaped particles, similar to non-heated VLPs
as shown in Figure 1b.
GagCAT VLPs before and after heat treatment are
immunogenic in mice
Since the aim of this work is to develop a vaccine that
does not transmit foreign RNAs but will maintain an
immune response to Gag, immune responses to single
vaccinations of GagCAT VLPs and heat treated Gag-
CAT VLPs were compared in BALB/c mice. In addition,
the effect of heating GagCAT VLPs on their ability to
boost a DNA vaccine prime (pTHGagC) was compared
to that of two vaccinations of pTHGagC. T cell
responses to a Gag CD8 peptide and two Gag CD4 pep-
tides (Gag CD4 (13) and Gag CD4 (17)) were measured
using IFN-g and IL-2 ELISPOT assays as the measure of
the immune response (Figure 3a). A VLP only vaccina-
tion induced a cumulative response to the Gag CD4(13)
and Gag CD4(17) peptides of 192 sfu/10
6 splenocytes in
the IFN-g ELISPOT assay while a heat treated GagCAT
VLP only inoculation induced a low response of 70 sfu/
10
6 splenocytes to the Gag CD4(13) peptide (Figure 3a).
No response to the Gag CD8 peptide was induced by
either VLP vaccine (Figure 3a). Both VLP preparations
boosted a primary response to pTHGagC and the mag-
nitudes of these responses were greater than the sum of
the responses to the individual priming and boosting
vaccines (Figure 3a). A cumulative response to the Gag
CD8 and Gag CD4 peptides of 1225 sfu/10
6 splenocytes
in the IFN-g ELISPOT assay was measured when Gag-
CAT VLPs were used as the boost while a cumulative
response to these peptides of 1637 sfu/10
6 splenocytes
was measured when heated GagCAT VLPs were the
boost vaccine. For the prime with pTHGagC and boost
with either VLP preparation Gag CD8 T cells contribu-
ted approximately 600 sfu/10
6 splenocytes to these
cumulative responses (Figure 3a). The higher response
achieved with the pTHGagC prime and heat treated
GagCAT VLP boost as opposed to a GagCAT VLP
boost was due to a greater frequency (2 fold) of
responding Gag-specific CD4 T cells. These responses
to a DNA prime and GagCAT VLP or heat-treated Gag-
CAT VLP boost were of higher magnitude than two
pTHGagC vaccinations which reached a cumulative
response of 892 sfu/10
6 splenocytes. The increase in
response to two DNA vaccinations is due to an increase
in responding Gag-specific IFN-g producing CD4 cells,
without a boost of the Gag CD8 cells. In comparison for
two DNA vaccinations CD4 T cells contribute 30% to
the overall response while CD4 T cells contribute 46%
and 66% to the overall response when the boost to a
DNA prime is either GagCAT VLPs or heated GagCAT
VLPs respectively (Figure 3a)
GagCAT VLP and heat-treated GagCAT VLP vaccina-
tions also induced Gag CD4+ cells that produced IL-2
with cumulative CD4 T cell frequencies of 153 sfu/10
6
splenocytes and 93 sfu/10
6 splenocytes respectively (Fig-
ure 3b). The prime-boost vaccination regimens induced
Gag CD8 and CD4 IL-2 producing T cells and the mag-
nitude of these responses were greater than the sum of
the responses to the individual priming and boosting
vaccines (Figure 3b). The sum of IL-2 producing Gag
CD8 and Gag CD4 T cells induced by pTHGagC were
boosted by GagCAT VLPs and heat treated GagCAT
VLPs to levels of 893 sfu/10
6 splenocytes and 1387 sfu/
10
6 splenocytes respectively. CD8+ cells contributed
similar frequencies of 310 sfu/10
6 splenocytes to these
total responses (Figure 3b). A pTHGag prime and hGag-
CAT VLP boost induced IL-2 producing CD4+ T cells
of 1061 sfu/10
6 splenocytes which is almost twice that
induced by the pTHGagC prime and GagCAT VLP
boost.
Conclusions
GagCAT VLPs that budded into the culture medium of
sf21 insect cells using the baculovirus expression system
were pseudotyped with baculovirus Gp64 envelope gly-
coprotein. Electron microscopic examination of the Gag-
CAT VLP preparation revealed that the cross-flow
filtration technique used to isolate the VLPs from the
culture supernatant successfully limited co-purification
of baculovirus particles to very low levels. In addition
CAT-encoding DNA carried by baculovirus particles in
the GagCAT VLP preparation was not detected by
CAT-specific PCR of the VLPs, which further supported
very low baculovirus contamination (Figure 1g).
Although Gp64 pseudotyping has been documented
[76], we now report that the Gp64 content of baculo-
virus-produced VLPs is very high relative to Gp120 on
HIV particles (~383 ng Gp64 per 1 μg Gag). HIV VLPs
of 120 to 150 nm in diameter are estimated to contain
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Page 7 of 12~5000 Gag proteins [77]. Thus each VLP contains
~1600 Gp64 molecules, or approximately 1 Gp64 mole-
cule for every 3 Gag molecules in each VLP. The num-
ber of glycoprotein envelope spikes on infectious HIV
virions was originally estimated to be approximately 72
[78], while more recent studies have indicated this num-
ber to be 2 to 14 trimers [78-81], which is sufficient to
mediate specific CD4+ T-cell entry. The far greater
number of baculovirus Gp64 molecules found on bacu-
lovirus-produced VLPs means these could very probably
mediate a baculovirus-specific mode and specificity of
cellular entry.
Previous research has shown that HIV particles that lack
envelope glycoproteins are most likely to be degraded in
a)
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Figure 3 Immune responses in mice vaccinated with GagCAT VLPs.I F N - g (A) and IL-2 (B) ELISPOT responses of groups of BALB/c mice to
Gag CD8 and Gag CD4 peptides on day 12 after vaccination with GagCAT VLPs (VLP) or heated GagCAT VLPs (hVLP) or pTHGagC and on day
40 for mice primed with pTHgagC then boosted on day 28 with VLPs or hVLPs. Splenocytes prepared from spleens combined from five mice
per group were used in IFN-g or IL-2 ELISPOT assays with the indicated Gag peptides. Bars are the mean number of spots of triplicate reactions
for 10
6 splenocytes with indicated standard deviation of the mean. Data is that from one of three replicate experiments.
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Page 8 of 12endocytic vesicles [39,41], indicating that the entry and
successful replication of HIV in mammalian cells is facili-
tated by the presence of glycoproteins on the outer surface
of the viral particle. The Gp64 pseudotyped GagCAT
VLPs containing a known quantity of encapsidated CAT
RNA were thus assayed in our uptake experiments using
BHK-21, HEK 293 and HeLa cells which are known to be
permissive to Gp64-mediated recombinant baculovirus
entry [54-56,58,60,61,74]. GagCAT VLPs were assumed to
be taken up by these cell lines as the encapsidated CAT
reporter RNA was successfully translated to produce CAT
protein. The CAT protein levels yielded were similar irre-
spective of the type of cell in which they were produced.
The encapsidated CAT RNA in our VLPs is representative
of other RNAs that are normally present in the VLP
expression system. To our knowledge, these results are the
first to document the Gp64-mediated uptake of VLPs
made using an insect cell expression system into mamma-
lian cells, and the subsequent expression of a reporter
RNA species encapsidated in the VLPs. Our results sug-
gest that there is a strong possibility that RNA which is
randomly encapsidated during VLP formation could be
successfully translated into protein once it has been taken
up by mammalian host cells. This finding contradicts pre-
vious assertions that baculovirus/insect cell-produced
HIV-Gag VLPs are non-"infectious” [76].
The VLP heat inactivation experiments showed that
heat treatment at 62°C reduced CAT protein levels in
lysates of two of the cell types tested (BHK-21 and
HeLa) to almost undetectable levels (Figure 2), which is
in agreement with results obtained using live virus parti-
cles [71,75]. The application of heat to the VLPs was
primarily to “disrupt” the particle surface structure: elec-
tron microscopic analysis of heat-treated VLPs showed
that heat treatment did not noticeably disrupt or lyse
the VLPs (Figure 1c). Heating of in vitro-transcribed
CAT RNA prior to transfection also had no effect on
CAT expression in the tested BHK-21 cell line (not
shown). We concluded from this that the inhibition of
CAT expression was most likely as a result of Gp64
damage on the GagCAT VLP surface. In the HEK 293
cells, CAT protein levels were relatively unaffected when
higher levels of encapsidated RNA were used in the cell
uptake assay. It is possible this is a result of the HEK-
293 cells employing an additional or alternate VLP cell
uptake pathway to that used by the BHK-21 and HeLa
cell lines. This variation in sensitivity to heat may be
cause for concern considering that a mixed population
of cell types may be present in the area of inoculation
when used as a vaccine in mammalian subjects. UV irra-
diation of VLPs has also been tested in this laboratory,
but this had little effect on abrogating or even decreas-
ing GagCAT transcription and translation (data not
shown).
With regard to particle immunogenicity, a literature
review has suggested that pseudotyping Gag VLPs with
functional/fusion competent envelope glycoproteins may
be of paramount importance in stimulating both MHC-I
and MHC-I Gag processing pathways [11,82-85]. It has
been shown that VLPs that did not display HIV-1 Env
were unable to induce immune responses that were
stronger than a DNA vaccine that produced soluble poly-
peptides [86]. In addition, HIV VLPs displaying HIV-
gp120 taken up by monocyte-derived dendritic cells
(MDDC) [87] showed enhanced Th1- and Th2-cytokine
production and were able to activate autologous naïve
CD4
+ T-cells and drive them towards a Th-1 response
[87]. Monkeys immunized with VSV-G pseudotyped SIV
particles generated SIV-specific humoral and cellular
immune responses, which significantly reduced peak vir-
aemia levels of a challenge virus. In mice, VSV-G-pseu-
dotyped HIV VLPs stimulated Gag-specific IgG and IgG1
antibody titres that were ~100 fold higher than non-
pseudotyped VLPs. As a control, a fusion defective VSV-
G was also displayed on the HIV VLPs and was not able
to enhance the VLP immune response. Insect cell-derived
HIV/SIV-derived VLPs that have no specific mammalian
virus-derived envelope glycoprotein have been found,
nevertheless, to efficiently stimulate the MHC-1-driven
CTL responses as well as humoral immune responses,
which may be a result of the presence of the baculovirus
Gp64 envelope glycoprotein [5,7,9,85,87-95].
The cellular immune response is partly dependent on
the successful entry of viruses into the cytoplasm of
the target cell resulting in viral replication rather than
viral particle degradation which stimulates the Th1
immune response. This kind of entry would be facili-
tated by receptor-mediated Gp64 interactions. If heat
treatment disrupts Gp64 on the Gag VLPs, successful
entry of VLPs into the target cell would not occur,
thus preventing a Th1 immune response to be stimu-
lated. However, we showed that VLP heat inactivation
did not appear to affect induction of subsequent
immune responses (Figure 3). GagCAT VLPs both
post-heating and unheated, induced low Gag-specific
CD4 IFN-g and IL-2 producing cells in mice and both
VLPs preparations boosted immune responses induced
by a primary DNA vaccine. It is not clear why a more
substantial boost of the Gag-specific CD4 T cell
response was observed with the hGagCAT VLPs. How-
ever, the VLP preparation only vaccinations and DNA
vaccine prime VLP boost vaccination regimens induced
magnitudes of Gag-specific immune responses as that
induced by Gag VLPs [7,68].
In summary, BEVS-produced HIV-1 Gag VLPs were
shown to be able to transfer and express foreign expres-
sion system-derived RNAs in mammalian cell lines.
Transfection of mammalian cells with heat-treated VLPs
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Page 9 of 12did not prevent RNA expression in all cell lines, but
reduced the range of cell lines that the VLPs could
enter and thus the range of cells into which RNA was
taken up. These results highlight the need to control the
nucleic acid content of assembled Gag particles notwith-
standing their need for random RNA encapsidation, cru-
cial for particle assembly. A possible alternative to limit
RNA encapsidation and hence transmission may lie with
creating chimeric gag particles that do not require RNA
for assembly, as has been shown by Crist et al., 2009
[96]. Chimeric Gag particles in which the nucleocapsid
domain had been replaced with a trimerizing leucine
zipper-domain showed an ability to assemble in 293T-
cells, which released particles that lacked any detectable
RNA. Future studies should investigate the feasibility of
producing these chimeric particles in insect cell lines
and assess their immunogenicity. Furthermore, where
RNA transmission is evident, the RNA uptake pathways
should be verified through the use of specific cell path-
way uptake inhibitors or antibodies specific for func-
tional receptors on the virion surface, such as Gp64.
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